Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cenisertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB known ✓ | Q96GD4 | 7/20 | 1.00 |
| ▸ | AURKA known ✓ | O14965 | 2/20 | 1.00 |
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 1.00 |
| ▸ | KDR | P35968 | 8/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 3/20 | 1.00 |
| ▸ | INSR | P06213 | 2/20 | 1.00 |
| ▸ | MET | P08581 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | SYK | P43405 | 2/20 | 1.00 |
| ▸ | CDC7 | O00311 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 1/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cenisertib SCHEMBL1079632 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL15169719 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL1000933 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL30097376 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL15290367 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL1066287 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL352432 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL1001874 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL10086258 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR | |
| Cenisertib SCHEMBL12972652 | 1.00 | IRAK4 (1.00) | IRAK4KDRAURKBALKINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546398-B2 | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | claimed |
| US-8044054-B2 | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-25 | — | — | US | claimed |
| US-8030483-B2 | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | claimed |
| US-11872227-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872227-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11357776-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200046698-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND AN AURORA KINASE INHIBITOR AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-9725419-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725419-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725419-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-8546398-B2 | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20070299060-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299060-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299060-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070179140-A1 | Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070179140-A1 | Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| EP-1763514-A2 | CYCLOALKYL SUBSTITUTED PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20060167249-A1 | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | US | disclosed |
| US-20060035891-A1 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | MIDCAP FINANCIAL TRUST | 2006-02-16 | — | — | US | disclosed |
| WO-2005118544-A2 | CYCLOALKYL SUBSTITUTED PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299060-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | AURKB 145/4885AURKA 422/4885IRAK4 4592/4885 |
| US-20070179140-A1 | Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, CCNI | AURKB 135/4885AURKA 256/4885IRAK4 4671/4885 |
| US-20060035891-A1 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | MKI67, PCNA, TK1 | AURKB 145/4885AURKA 422/4885IRAK4 4592/4885 |
| US-20060167249-A1 | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses | MKI67, PCNA, CCNI | AURKB 135/4885AURKA 256/4885IRAK4 4671/4885 |
| US-11872227-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | HDAC1, HDAC3, HDAC8 | AURKB 15/4885AURKA 23/4885IRAK4 1184/4885 |
| US-20200046698-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND AN AURORA KINASE INHIBITOR AND METHODS OF USE THEREOF | HDAC1, HDAC3, HDAC8 | AURKB 15/4885AURKA 23/4885IRAK4 1184/4885 |
| US-11357776-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof | HDAC1, HDAC3, HDAC8 | AURKB 15/4885AURKA 23/4885IRAK4 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.